Structural basis of HIV-1 and HIV-2 protease inhibition by a monoclonal antibody
Language English Country United States Media print
Document type Comparative Study, Journal Article, Research Support, Non-U.S. Gov't
PubMed
11591344
DOI
10.1016/s0969-2126(01)00654-2
PII: S0969212601006542
Knihovny.cz E-resources
- MeSH
- Aspartic Acid Endopeptidases chemistry immunology metabolism MeSH
- Models, Chemical MeSH
- HIV Protease chemistry immunology metabolism MeSH
- Immunoglobulin Fab Fragments chemistry metabolism MeSH
- HIV Protease Inhibitors chemistry pharmacology MeSH
- Protein Conformation MeSH
- Crystallography, X-Ray MeSH
- Models, Molecular MeSH
- Antibodies, Monoclonal chemistry pharmacology MeSH
- Peptide Fragments immunology metabolism MeSH
- Antibodies, Viral chemistry metabolism MeSH
- Binding Sites, Antibody MeSH
- Cross Reactions MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Comparative Study MeSH
- Names of Substances
- Aspartic Acid Endopeptidases MeSH
- HIV Protease MeSH
- Immunoglobulin Fab Fragments MeSH
- HIV Protease Inhibitors MeSH
- Antibodies, Monoclonal MeSH
- p16 protease, Human immunodeficiency virus 2 MeSH Browser
- Peptide Fragments MeSH
- Antibodies, Viral MeSH
BACKGROUND: Since the demonstration that the protease of the human immunodeficiency virus (HIV Pr) is essential in the viral life cycle, this enzyme has become one of the primary targets for antiviral drug design. The murine monoclonal antibody 1696 (mAb1696), produced by immunization with the HIV-1 protease, inhibits the catalytic activity of the enzyme of both the HIV-1 and HIV-2 isolates with inhibition constants in the low nanomolar range. The antibody cross-reacts with peptides that include the N terminus of the enzyme, a region that is highly conserved in sequence among different viral strains and that, furthermore, is crucial for homodimerization to the active enzymatic form. RESULTS: We report here the crystal structure at 2.7 A resolution of a recombinant single-chain Fv fragment of mAb1696 as a complex with a cross-reactive peptide of the HIV-1 protease. The antibody-antigen interactions observed in this complex provide a structural basis for understanding the origin of the broad reactivity of mAb-1696 for the HIV-1 and HIV-2 proteases and their respective N-terminal peptides. CONCLUSION: A possible mechanism of HIV-protease inhibition by mAb1696 is proposed that could help the design of inhibitors aimed at binding inactive monomeric species.
References provided by Crossref.org
Optimization of the crystallizability of a single-chain antibody fragment
PDB
1JP5
